MDXHEALTH: Back on the rails and looking to accelerate MDXH BB
MDxHealth seems to have turned the corner from a turbulent period, refocussing on growth as the business stabilizes. While ConfirmMDx provides a solid base to grow from short-term, SelectMDx’ LCD coverage is anticipated as the next catalyst pushing the company in a higher gear. Although Covid-19 may have slowed down the MDx train, it has demonstrated resilience and remains on the right trajectory. As such, we upgrade to BUY (Hold) and raise our TP to € 1.0 (30% upside).MDxHealth is a molecular diagnostics company that develops and commercializes epigenetic assays and service testing for cancer assessment and the personalized treatment of patients. Co. offers two main products: Clinical Molecular Diagnostics (ClinicalMDx) Solutions that provide physicians with tests for the identification and treatment of their cancer patients; and Pharmaco Molecular Diagnostics (PharmacoMDx) Solutions for the development of companion diagnostics, biomarker discovery, and clinical trial testing. Co.'s ClinicalMDx solutions include ConfirmMDx, InformMDx, RecurMDx, and PredictMDx.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.